ClinicalTrials.gg
CompletedNCT03403959Updated Sep 16, 2020

Seasonal Affective Disorder and Visual Impairment

An interventional study of light therapy in Seasonal Affective Disorder and Visual Impairment, sponsored by Psychiatric Centre Rigshospitalet. Completed at 1 site in Denmark. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Psychiatric Centre Rigshospitalet · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

As a subtype of major depressive disorder, seasonal affective disorder (SAD) or winter depression causes severe reductions in both quality of life and productivity and results in high morbidity and frequent sick leave (1). SAD is a prevalent disorder with rates as high as 3-5% in central European countries and 8-10% in Scandinavian countries. In our recent screening survey among persons with severe visual impairment or blindness (visual acuity \< 6/60), we found a strikingly high prevalence of SAD of 17 % compared to 8% in the fully sighted control group. Persons with maintained light perception had a highly increased SAD prevalence of 18 % whereas no light perception (NLP) respondents had an SAD prevalence of 13 %. Light is unquestionably of great importance in the development and treatment of SAD. It is suggested that a reduced retinal sensitivity to light leads to sub-threshold light input to the brain and consequently to the development of SAD. The novel retinal non-visual photoreceptors, the intrinsically photosensitive retinal ganglion cells (ipRGCs), are involved in the regulation of circadian rhythm and mood and their function are in part independent of the function of the classical rod and cone photoreceptors which form the basis of conscious visual perception. Function of the ipRGCs can be assessed by chromatic pupillometry where the sustained pupillary contractions following blue light stimulation (PIPR) is the main outcome. In persons with SAD without eye disorder the function of the ipRGCs is reduced. We here wish to investigate associations between ipRGC function and SAD symptoms, circadian profile and treatment response to light therapy in persons with visual impairment.

Persons with visual impairment (SAD and non-SAD) are assessed for ipRGC function with chromatic pupillometry, for seasonal mood variation by interview and questionnaire and for diurnal melatonin secretion by saliva analysis summer and winter. In winter SAD participants are treated with daily morning bright light for 6 weeks. Reduction in depression scores and tolerability is recorded.

02

Conditions studied

  • Seasonal Affective Disorder
  • Visual Impairment

Keywords

  • pupillometry
  • light therapy
  • visual impairment
  • melatonin
  • ipRGC
03

In context

Seasonal Affective Disorder

31 studies on the registry are indexed under Seasonal Affective Disorder; 2 are open to participants now.

This study's enrollment of 18 is below the median of 60 across 25 interventional studies indexed under Seasonal Affective Disorder.

Browse Seasonal Affective Disorder studies →

Lead sponsor

Psychiatric Centre Rigshospitalet is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Seasonal affective disorder. Visual impairment (Snellen visual acuity \< 6/18) or visual field reduction (MD\<10).

Exclusion criteria

Exclusion Criteria:

Alcohol or drug abuse. Current or planned pregnancy. Other neuropsychiatric disorder. Antidepressant medication. Regular use of melatonin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    SAD

    Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.

    Device: light therapy

  • No intervention
    non-SAD

    Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.

Interventions

  • Devicelight therapy

    6 weeks morning treatment with bright light therapy in own home.

06

What researchers measure

Primary outcomes

  1. treatment response

    Reduction in depression severity on the Structured interview guide for the Hamilton Depression Rating Scale - Seasonal affective disorder version (25 items version total score with range 0-78. Results from Hamilton Rating Scale for Depression 17 items (range 0-52) and the 8 item atypical symptom subscale (range 0-26) are reported. Higher scores indicate higher severity.

    Time frame: 6 weeks

  2. saliva melatonin concentration

    Differences in melatonin secretion as indicated by area under curve (AUC) between SAD and non-SAD (summer and winter).

    Time frame: 6 months

Secondary outcomes

  1. PIPR - light therapy

    Correlation between treatment response and ipRGC function as measured by the sustained (10-20 seconds) post-illumination pupillary contraction following blue light stimulation

    Time frame: 6 weeks

Other outcomes

  1. feasibility of light therapy

    side effects and tolerability of light therapy

    Time frame: 6 weeks

  2. Late sustained post-illumination pupillary response to blue light

    Difference in late PIPR (10-30 seconds post-illumination) following high intensity blue light between SAD and non-SAD and between seasons

    Time frame: 6 months

07

Study locations

1 site
  • Mental Health Center Copenhagen
    Copenhagen Ø, 2100, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03403959
Lead sponsor
Psychiatric Centre Rigshospitalet
Responsible party
Helle Østergaard Madsen (MD, Psychiatric Centre Rigshospitalet) — Principal investigator
First posted
Jan 19, 2018
Start date
Dec 1, 2017
Primary completion
Mar 12, 2020
Completion
Mar 12, 2020
Last update
Sep 16, 2020

Study contacts

Helle Ø Madsen, MD
principal investigator · Mental Health Center Copenhagen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion